TGF-β 抑制与免疫治疗：Checkmate.
TGF-β Inhibition and Immunotherapy: Checkmate.
机构信息
Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Department of Medicine, Memorial Hospital, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
出版信息
Immunity. 2018 Apr 17;48(4):626-628. doi: 10.1016/j.immuni.2018.03.037.
Abstract
Immune checkpoint therapy can induce durable remissions, but many tumors demonstrate resistance. In a recent issue of Nature, Mariathasan et al. (2018) and Tauriello et al. (2018) identify stromal TGF-β signaling as a determinant of immune exclusion. Combination TGF-β inhibition and immunotherapy induces complete responses in mouse models.
摘要
免疫检查点疗法可以诱导持久缓解，但许多肿瘤表现出耐药性。在最近一期的《自然》杂志上，Mariathasan 等人（2018 年）和 Tauriello 等人（2018 年）发现基质 TGF-β 信号作为免疫排斥的决定因素。联合 TGF-β 抑制和免疫疗法可在小鼠模型中诱导完全反应。
相似文献
1
TGF-β Inhibition and Immunotherapy: Checkmate.TGF-β 抑制与免疫治疗：Checkmate.
Immunity. 2018 Apr 17;48(4):626-628. doi: 10.1016/j.immuni.2018.03.037.
2
Blockade of TGF-β signaling: a potential target for cancer immunotherapy?阻断 TGF-β 信号通路：癌症免疫治疗的潜在靶点？
Expert Opin Ther Targets. 2019 Aug;23(8):679-693. doi: 10.1080/14728222.2019.1636034. Epub 2019 Jun 27.
3
CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.基于预测性综合免疫比值的 CD25 和 TGF-β 阻断抑制胰腺癌肿瘤生长。
J Transl Med. 2018 Oct 25;16(1):294. doi: 10.1186/s12967-018-1673-6.
4
Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.联合抑制 TGF-β 信号和 PD-L1 免疫检查点在肿瘤模型中具有不同的疗效。
Cells. 2019 Apr 5;8(4):320. doi: 10.3390/cells8040320.
5
Immune checkpoint blockade combined with IL-6 and TGF-β inhibition improves the therapeutic outcome of mRNA-based immunotherapy.免疫检查点阻断联合 IL-6 和 TGF-β 抑制可改善基于 mRNA 的免疫治疗的治疗效果。
Int J Cancer. 2018 Aug 1;143(3):686-698. doi: 10.1002/ijc.31331. Epub 2018 Mar 13.
6
Combined delivery of a TGF-β inhibitor and an adenoviral vector expressing interleukin-12 potentiates cancer immunotherapy.联合递送 TGF-β 抑制剂和表达白细胞介素-12 的腺病毒载体增强癌症免疫治疗。
Acta Biomater. 2017 Oct 1;61:114-123. doi: 10.1016/j.actbio.2017.05.009. Epub 2017 May 5.
7
Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy.转化生长因子-β的肽类抑制剂可增强抗肿瘤免疫疗法的疗效。
Int J Cancer. 2009 Dec 1;125(11):2614-23. doi: 10.1002/ijc.24656.
8
The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.当前恶性胶质瘤免疫治疗的失败。肿瘤源性转化生长因子-β、T细胞凋亡与脑的免疫豁免权。
Brain Res Brain Res Rev. 1995 Sep;21(2):128-51. doi: 10.1016/0165-0173(95)00010-0.
9
Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8 T-cells Derived from Patients with Metastatic Castrate-resistant Disease.针对转移性去势抵抗性疾病患者来源的、前列腺特异性膜抗原特异性、转化生长因子-β 不敏感的基因靶向 CD8 T 细胞对人前列腺癌的疗效。
Eur Urol. 2018 May;73(5):648-652. doi: 10.1016/j.eururo.2017.12.008. Epub 2017 Dec 21.
10
Turning Cold Tumors Hot by Blocking TGF-β.通过阻断转化生长因子-β使冷肿瘤变热
Trends Cancer. 2018 May;4(5):335-337. doi: 10.1016/j.trecan.2018.03.005. Epub 2018 Mar 30.
引用本文的文献
1
Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy.肠道微生物群重塑肿瘤微环境并影响结直肠癌免疫治疗的疗效。
Cancer Med. 2025 Jun;14(12):e70994. doi: 10.1002/cam4.70994.
2
Redirecting immune signaling with cytokine adaptors.利用细胞因子衔接蛋白重定向免疫信号传导。
Nat Commun. 2025 Mar 11;16(1):2432. doi: 10.1038/s41467-025-57681-1.
3
Blockade of Arf1-mediated lipid metabolism in cancers promotes tumor infiltration of cytotoxic T cells via the LPE-PPARγ-NF-κB-CCL5 pathway.阻断癌症中Arf1介导的脂质代谢通过LPE-PPARγ-NF-κB-CCL5途径促进细胞毒性T细胞的肿瘤浸润。
Life Metab. 2023 Sep 6;2(5):load036. doi: 10.1093/lifemeta/load036. eCollection 2023 Oct.
4
Combination of polymeric micelle formulation of TGFβ receptor inhibitors and paclitaxel produces consistent response across different mouse models of Triple-negative breast cancer.转化生长因子β受体抑制剂的聚合物胶束制剂与紫杉醇联合使用，在不同的三阴性乳腺癌小鼠模型中均产生了一致的反应。
Bioeng Transl Med. 2024 Jun 4;9(5):e10681. doi: 10.1002/btm2.10681. eCollection 2024 Sep.
5
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies.优化 CAR-T 细胞疗法治疗实体瘤：当前挑战与潜在策略。
J Hematol Oncol. 2024 Nov 5;17(1):105. doi: 10.1186/s13045-024-01625-7.
6
Specific Deletions of Chromosomes 3p, 5q, 13q, and 21q among Patients with G2 Grade of Non-Small Cell Lung Cancer.非小细胞肺癌 G2 级患者中染色体 3p、5q、13q 和 21q 的特定缺失。
Int J Mol Sci. 2024 Aug 8;25(16):8642. doi: 10.3390/ijms25168642.
7
Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma.武装双顺反子嵌合抗原受体 T 细胞的显性负性 TGF-β 受体 II 以克服胶质母细胞瘤的耐药性。
Mol Ther. 2024 Oct 2;32(10):3522-3538. doi: 10.1016/j.ymthe.2024.07.020. Epub 2024 Jul 31.
8
Codelivery of TGFβ and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to Immune Checkpoint Inhibitors.转化生长因子β（TGFβ）与环氧化酶2（Cox2）小干扰RNA（siRNA）的共递送通过促进T细胞渗入肿瘤来抑制肝癌，并改善对免疫检查点抑制剂的反应。
NAR Cancer. 2024 Jan 9;6(1):zcad059. doi: 10.1093/narcan/zcad059. eCollection 2024 Mar.
9
Tumor metabolic crosstalk and immunotherapy.肿瘤代谢的串扰与免疫治疗。
Clin Transl Oncol. 2024 Apr;26(4):797-807. doi: 10.1007/s12094-023-03304-4. Epub 2023 Sep 23.
10
Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1.病例报告：使用靶向转化生长因子-β（TGF-β）和程序性死亡受体配体1（PD-L1）的双功能融合蛋白PM8001治疗后引发的角化棘皮瘤和I型糖尿病。
Front Oncol. 2023 Aug 1;13:1046266. doi: 10.3389/fonc.2023.1046266. eCollection 2023.
本文引用的文献
1
Cancer immunotherapy using checkpoint blockade.使用免疫检查点阻断的癌症免疫疗法。
Science. 2018 Mar 23;359(6382):1350-1355. doi: 10.1126/science.aar4060. Epub 2018 Mar 22.
2
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis.TGFβ 驱动基因重建的结肠癌转移中的免疫逃逸。
Nature. 2018 Feb 22;554(7693):538-543. doi: 10.1038/nature25492. Epub 2018 Feb 14.
3
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.TGFβ 通过促使 T 细胞排除而减弱肿瘤对 PD-L1 阻断的反应。
Nature. 2018 Feb 22;554(7693):544-548. doi: 10.1038/nature25501. Epub 2018 Feb 14.
4
Combination immunotherapy: a road map.联合免疫疗法：路线图。
J Immunother Cancer. 2017 Feb 21;5:16. doi: 10.1186/s40425-017-0218-5. eCollection 2017.
5
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.基于检查点抑制剂的免疫疗法的预测性生物标志物。
Lancet Oncol. 2016 Dec;17(12):e542-e551. doi: 10.1016/S1470-2045(16)30406-5.
6
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.癌症免疫疗法的下一个障碍：克服非T细胞炎症性肿瘤微环境
Semin Oncol. 2015 Aug;42(4):663-71. doi: 10.1053/j.seminoncol.2015.05.011. Epub 2015 Jun 3.
7
Stromal gene expression defines poor-prognosis subtypes in colorectal cancer.基质基因表达定义了结直肠癌的预后不良亚型。
Nat Genet. 2015 Apr;47(4):320-9. doi: 10.1038/ng.3225. Epub 2015 Feb 23.
8
Targeting the TGFβ pathway for cancer therapy.针对癌症治疗的 TGFβ 通路。
Pharmacol Ther. 2015 Mar;147:22-31. doi: 10.1016/j.pharmthera.2014.11.001. Epub 2014 Nov 6.
9
The roles of TGFβ in the tumour microenvironment.TGFβ 在肿瘤微环境中的作用。
Nat Rev Cancer. 2013 Nov;13(11):788-99. doi: 10.1038/nrc3603. Epub 2013 Oct 17.
10
TGFβ signalling in context.TGFβ 信号通路在语境中的作用。
Nat Rev Mol Cell Biol. 2012 Oct;13(10):616-30. doi: 10.1038/nrm3434. Epub 2012 Sep 20.
Zotero 插件